Skip to content

Risk communication about high-dose MDMA: Impact of a hypothetical drug alert on future MDMA use.

Joel Keygan, Breanna Willoughby, Raimondo Bruno, Monica J Barratt, Amy Peacock

Drug and Alcohol Review May 1, 2025 DOI: 10.1111/dar.14037 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Peer reviewed
Sample size 625
Population Australians who used MDMA pills or capsules in the past year
Interventions effects and actions to reduce harm
Topics MDMA
Keywords Drug safety alerts MDMA/Ecstasy/Molly Public health interventions Behaviour change Drug alerts Harm reduction Risk communication
Citations 1
Key findings Receipt of a high-dose MDMA drug alert was associated with greater intention to not use the drug or to reduce the initial dose, compared to no alert, but variations in alert phrasing did not significantly affect intended behavior.

Abstract

Despite high-dose 3,4-methylenedioxymethamphetamine (MDMA) drug alerts being distributed, no research has been conducted as to changes in use in response. This study aimed to determine if: (i) high-dose MDMA drug alerts, and (ii) varied descriptions of dose, effects and actions to reduce harm were associated with intentions to reduce the initial MDMA dose in a hypothetical scenario. Australians who used MDMA pills/capsules in the past year completed an online survey. Respondents were randomised into alert (n = 441) or control (n = 184) conditions, with the former receiving a high-dose MDMA alert with systematically varied descriptions of dose, effects and actions to reduce harm. Multinomial logistic regressions determined the association between receipt of drug alert (and varying alert content) and hypothetical MDMA dosing. Almost half (45.4%) of those in any alert condition reported intention to not use (20.7% of control participants) and 46.7% stated they would use and reduce their initial dose (69.0% of control group). Compared to the control group, those who received an alert were significantly more likely to report intention to not use the drug, as compared to taking a smaller initial dose (adjusted relative risk ratio [aRRR] = 3.28, 95% confidence interval [CI] 2.13, 5.07) or taking the same/higher initial dose (aRRR = 2.62, 95% CI 1.31, 5.22). There was no significant association between different alert phrasing and intended behaviour. While there was no significant effect of variation in phrasing, receipt of an alert promoted intended harm reduction behaviours. Future research assessing actual behaviour and different substances (e.g., heroin, methamphetamine) is important to further understand the utility of this public health communication.

Comparable studies

Other randomized controlled trials on MDMA, most cited first.

Study Year Design Participants
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Patients with severe PTSD, including those with comorbidities such as dissociation,... 2021 Randomized controlled trial n = 90
The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Patients with chronic post-traumatic stress disorder refractory to both psychotherapy... 2010 Randomized controlled trial n = 20
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Military veterans and first responders aged 18 or older with chronic PTSD lasting 6... 2018 Randomized, double-blind, dose-response, phase 2 clinical trial n = 26
A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD) Patients with treatment-resistant PTSD 2012 Randomized controlled trial n = 12
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Adults with moderate to severe post-traumatic stress disorder 2023 Randomized controlled trial n = 104

Citations in the library

Explore topics